Skip to main content
Journal cover image

Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines.

Publication ,  Journal Article
Clay, TM; Osada, T; Hartman, ZC; Hobeika, A; Devi, G; Morse, MA; Lyerly, HK
Published in: Immunol Res
April 2011

Aberrant signaling pathways are a hallmark of cancer. A variety of strategies for inhibiting signaling pathways have been developed, but monoclonal antibodies against receptor tyrosine kinases have been among the most successful. A challenge for these therapies is therapeutic unresponsiveness and acquired resistance due to mutations in the receptors, upregulation of alternate growth and survival pathways, or inadequate function of the monoclonal antibodies. Vaccines are able to induce polyclonal responses that can have a multitude of affects against the target molecule. We began to explore therapeutic vaccine development to antigens associated with these signaling pathways. We provide an illustrative example in developing therapeutic cancer vaccines inducing polyclonal adaptive immune responses targeting the ErbB family member HER2. Further, we will discuss new strategies to augment the clinical efficacy of cancer vaccines by enhancing vaccine immunogenicity and reversing the immunosuppressive tumor microenvironment.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Immunol Res

DOI

EISSN

1559-0755

Publication Date

April 2011

Volume

49

Issue

1-3

Start / End Page

235 / 247

Location

United States

Related Subject Headings

  • Trastuzumab
  • T-Lymphocytes
  • Signal Transduction
  • Receptor, erbB-2
  • Receptor, ErbB-2
  • Quinazolines
  • Protein-Tyrosine Kinases
  • Neoplasms
  • Lapatinib
  • Immunotherapy
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Clay, T. M., Osada, T., Hartman, Z. C., Hobeika, A., Devi, G., Morse, M. A., & Lyerly, H. K. (2011). Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines. Immunol Res, 49(1–3), 235–247. https://doi.org/10.1007/s12026-010-8186-6
Clay, Timothy M., Takuya Osada, Zachary C. Hartman, Amy Hobeika, Gayathri Devi, Michael A. Morse, and H Kim Lyerly. “Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines.Immunol Res 49, no. 1–3 (April 2011): 235–47. https://doi.org/10.1007/s12026-010-8186-6.
Clay TM, Osada T, Hartman ZC, Hobeika A, Devi G, Morse MA, et al. Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines. Immunol Res. 2011 Apr;49(1–3):235–47.
Clay, Timothy M., et al. “Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines.Immunol Res, vol. 49, no. 1–3, Apr. 2011, pp. 235–47. Pubmed, doi:10.1007/s12026-010-8186-6.
Clay TM, Osada T, Hartman ZC, Hobeika A, Devi G, Morse MA, Lyerly HK. Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines. Immunol Res. 2011 Apr;49(1–3):235–247.
Journal cover image

Published In

Immunol Res

DOI

EISSN

1559-0755

Publication Date

April 2011

Volume

49

Issue

1-3

Start / End Page

235 / 247

Location

United States

Related Subject Headings

  • Trastuzumab
  • T-Lymphocytes
  • Signal Transduction
  • Receptor, erbB-2
  • Receptor, ErbB-2
  • Quinazolines
  • Protein-Tyrosine Kinases
  • Neoplasms
  • Lapatinib
  • Immunotherapy